Vireo Growth (VREOF) Profit After Tax (2020 - 2026)
Vireo Growth (VREOF) posted Profit After Tax of -$20.3 million for Q1 2026, little changed sequentially from -$20.4 million in Q4 2025, and down 212.31% YoY from $18.1 million in Q1 2025.
Vireo Growth (VREOF) Profit After Tax (2020 - 2026) Analysis & Trends
Vireo Growth has reported Profit After Tax for 7 years, with the latest figure at -$20.3 million in Q1 2026.
- Quarterly Profit After Tax fell 212.31% year-over-year to -$20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.9 million (down 194.66% YoY) and the FY2025 annual result came in at -$68.1 million, down 143.2% from the prior year.
- Profit After Tax held at -$20.3 million in Q1 2026 per VREOF's latest filing, from -$20.4 million in the prior quarter.
- Over five years, Profit After Tax peaked at -$668411.0 in Q2 2024 and troughed at -$26.3 million in Q3 2025.
- A 5-year average of -$10.8 million and a median of -$8.4 million in 2023 frame the typical range for Profit After Tax.
- The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 90.88% in 2024, then tumbled 2134.26% in 2025.
- Over 5 years, Profit After Tax stood at -$13.3 million in 2022, then soared by 65.5% to -$4.6 million in 2023, then plunged by 242.61% to -$15.7 million in 2024, then retreated by 29.75% to -$20.4 million in 2025, then grew by 0.35% to -$20.3 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$20.3 million, -$20.4 million, and -$26.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 710.56 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Vireo Growth | 493.25 Mn | 350.95 Mn | 95.30 Mn | -100,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.30 Mn |
| Dec 31, 2025 | -20.37 Mn |
| Sep 30, 2025 | -26.30 Mn |
| Jun 30, 2025 | -14.93 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | -4.93 Mn |
| Jun 30, 2024 | -668,411.00 |
| Mar 31, 2024 | -6.71 Mn |
| Dec 31, 2023 | -4.58 Mn |
| Sep 30, 2023 | -5.23 Mn |
| Jun 30, 2023 | -7.33 Mn |
| Mar 31, 2023 | -8.41 Mn |
| Dec 31, 2022 | -13.28 Mn |
| Sep 30, 2022 | -8.42 Mn |
| Jun 30, 2022 | -6.18 Mn |
| Mar 31, 2022 | -14.57 Mn |
| Dec 31, 2021 | -12.93 Mn |
| Sep 30, 2021 | -6.87 Mn |
| Jun 30, 2021 | -7.01 Mn |